close

References

1. Brown WS, Tan L, Smith A, Gray NS, Wendt MK. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Mol Cancer Ther. 2016;15(9):2096-2106. 
2. Akhand SS, Liu Z, Purdy SC, et al. Pharmacologic inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade. Cancer Immunol Res. 2020;8(12):1542-1553.
3. Palakurthi S, Kuraguchi M, Zacharek SJ, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7(9):1457-1471. 
4. Lamarca A, Palmer DH, Singh Wasan H, et al. A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. 2019 ASCO Annual Meeting; Chicago, IL. Abs 4003. 
5. Vogel A, Sahai V, Hollebecque A, et al. FIGHT-202: a phase 2 study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). ESMO Congress 2019. Barcelona, Spain. Abs LBA40.